Clinical Trials Logo

Clinical Trial Summary

The purpose of this study was to identify genetic, brain morphologic, and environmental biomarkers that contribute to the pathophysiology of attention-deficit/hyperactivity disorder (ADHD).


Clinical Trial Description

The investigators planned to recruit ADHD and healthy controls from the age of 6 to 17.

Genetic data including dopamine, norepinephrine, serotonin, neurotropic factors, glutamate-related genes will be genotyped.

Environmental disruptors including phthalate and cotinine will be analyzed. Brain MRI data including T1, diffusion tensor imaging (DTI), resting state functional MRI (rsfMRI) will be obtained.

Neuropsychological tests including continuous performance test, Stroop test, Children's color trail test, Wisconsin card sorting test will be conducted.

The investigators plan to identify biomarkers of ADHD using an integrative approach of genetic, environmental, neuroimaging and clinical data. ;


Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention-deficit/Hyperactivity Disorder
  • Hyperkinesis

NCT number NCT02623114
Study type Interventional
Source Seoul National University Childrens Hospital
Contact Johanna IH Kim, MD
Email iambabyvox@hanmail.net
Status Recruiting
Phase Phase 4
Start date May 2012
Completion date March 2017

See also
  Status Clinical Trial Phase
Completed NCT02251743 - Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD N/A
Completed NCT02226445 - Treatment Drop-out and Missed Appointments Among Adults With ADHD N/A
Completed NCT01342445 - Effects of LDX on Functioning of College Students With ADHD Phase 4
Not yet recruiting NCT00391495 - Inflammation in Children With Attention-Deficit/Hyperactivity Disorder N/A
Completed NCT00528697 - A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 2
Completed NCT00494819 - Validity of ADHD Subtypes Using Neuropsychological Measure N/A
Completed NCT02217371 - Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in Adult Patients With Attention Deficit Disorder With or Without Hyperactivity N/A
Completed NCT01081132 - Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl Phase 3
Completed NCT06064942 - Multiple Family Narrative Therapy for Chinese Families of Children With Attention Deficit Hyperactivity Disorder N/A
Completed NCT00391729 - A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 2
Completed NCT00191048 - Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD Phase 4
Terminated NCT00554385 - A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 2
Completed NCT00997984 - Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study) Phase 3
Not yet recruiting NCT05568446 - Social VR Based Intervention on Enhancing Social Interaction Skills in Children With AD/HD N/A
Completed NCT02096952 - Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD Phase 4
Completed NCT01351246 - Guided Self-Help for Parents of Children With Attention-Deficit/Hyperactivity Disorder (ADHD) N/A
Completed NCT00686933 - Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 2
Completed NCT00491647 - Time Perception Deficits and Attention-Deficit/Hyperactivity Disorder N/A
Completed NCT01081145 - Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) Phase 3
Recruiting NCT06185985 - Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms Phase 4